<FEFF F30D5309A30ED30AF309930E930E0005F E E C83DD004C8A C0018DF38000DD2E >
|
|
|
- めぐの のじま
- 5 years ago
- Views:
Transcription
1 CARTO ipv Carto3 5V Thermocool 37 ipv ipv 36 ipv 44 9 ipv ipv 34/62 ipv 553/20 ipv 15 P V capture block P AM
2 J Arrhythmia Vol 28 Suppl 2012 trigger Lasso Repeat session Repeat session Repeat session / / P 0.01 myocardial slleve ablation strategy ATP dormant conduction ATP dormant conduction ATP ATP20 mg dormant conduction roof line mitral isthmus line W ATP 4 25 dormant conduction Dormant conduction lateral dormant conduction 1 3 ATP ATP dormant conduction Dormant conduction
3 dormant conduction ATP dormant conduction ATP dormant conduction ATP 20 V1 isoelectric line flat line AFL F F 3 CARTO en trainment AFL 128 AFL 12 F isoelectric line IEL flat line FL CARTO activation voltage F com mon AFL CO n 65 reverse common AFL RC mgatp ATP 0.16 mg/kg ATP ATP DP ATP P ATP ATP 6 7 DP ATP p 0.04 ATP DP ATP vs p ATP ATP 4 5DP ATP 2 5 ATP n 17 upper loop reentry ULR n 6 lower loop reentry LLR n 6 other reentry in right atrium n 6 perimitral AFL PM n 21 pulmonary vein related AFL PVR n 7 V1 RC LLR AFL IEL 13/17 5/6 vs 5/98 P 0.01 FL CO PM PVR 44/63 16/21 6/7 vs 5/35 P 0.01 CO PM PVR IEL 53/65 9/19 vs 0/7 P 0.01 P 0.05 CO PM V1 PM IEL FL 10/19 vs 19/65 P 0.05 CO PM mv vs mv P mv vs mv P NS V1 IEL FL AFL 7 6 AM
4 J Arrhythmia Vol 28 Suppl 2012 PVI 120 PVI PVI 2 1 X PVI PVI Lasso y positive hump PH negative hump NH PH NH PVI hump PH NH r PH NH 1 PH 3 NH 1 PH NH PVI P P P wave late potential P LP P LP P P PWD root mean squared voltage of the terminal 20 msec RMS20 PWD 130 msec RMS V P LP P LP P LP PWD to msec p RMS to V p P LP 80 vs. 33 p 0.02 PWD 2 27 vs msec p 0.02 RMS vs V p 0.07 P LP OR 9.2 p 0.03 P LP P LP
5 P wave duration P P filtered P wave duration FPD PVI FPD PVI FPD EEPVI AF 2nd AF EEPVI CARTO mapping multifocal AT 1 72 long RP tachycardia CL370 msec VA linking AT AT CARTO mapping activation mapping 10 2 FPD FPD FPD n FPD n FPD 2 2nd follow up FPD 1st 2nd FPD 2 FPD 12 1st FPD 2 weeks vs p FPD 12 weeks vs p FPD 10 AT2 CL350 msec AT3 CL285 msec AT3 retrospective AT AT1 AT2 AT3 3 AT CARTO activation mapping centrifugal pattern AT 7 6 AM
6 J Arrhythmia Vol 28 Suppl CHADS MMP 2 TIMP 2 CITP PINP prothrombin fragment1 2 TGF 1 TNFIL 6 CRP LDL ANP BNP CHADS vs p 0.01 BNP vs p vs p BNP vs p 0.04 IL vs p 0.04 BNP vs p 0.04 IL vs p 0.03 BNP IL 6 Complex Fractionated Atrial Electrogram PersAF complex fractionated atrial electrogram CFAE CFAE Jadidi Circ AE 2012PersAF CFAE PersAF CFAE Non CFAE CFAE Ashihara Circ Res 2012 PersAF in silico 1 PersAF Fb Area CFAE CFAE Fb Area CFAE 2 PersAF CFAE Non CFAE 7 CFAE CFAE
7 Pulmonary Vein Antrum Isolation conduction gap PV map EP Expert Doctors Team Tsuchiya AF pulmonary vein antrum isolation PVAI PV map Circ J PV antrum activation pattern geometry PV antum one round ablation ablation line conduction gap PV map Independent PV tachycardia Independent PV tachycardia i PVT i PVT i PVT 501 i PVT i PVT 1 Group1 2 Group2 3 i PVT Group3 i PVT 16 PV antrum PVAI /AF 8/2 PV map NavX 20 PV PV pacing 27 PV PV map / map Conduction gap 1PV mv 71 fractionated electrogram 24 PV PVAI ablation line 1gap PVAI PV map PV antrum / 8/8 Group1 9 Group2 4 Group3 3 i PVT ms i PVT i PVT i PVT i PVT 7 6 AM
8 J Arrhythmia Vol 28 Suppl 2012 I C PVI Complex fractionated atrial electrogram CFAE I C I CTP PVI CFAE 34 I CTP mm I CTP 3.5 ng/ml vs. 3.0 ng/ml p I CTP R 0.51 p Figure 1 Kaplan Meier I CTP Figure 2 I CTP Guillain Barre J Guillain Barre GBS GBS J J GBS J GBS GBS PQ QRS QTc mean SD ms ms ms J mv 9 25 J 89 vs 11 p J vs mv p GBS J
9 PVC 64 PVC PVC MC 6400 QRS Brugada T wave Alternans Brugada BS T wave Alternans TWA BS TWA BS 89 BS S BS N 17 BS A BS N 72 Controls N 7 GE Healthcare Seer Light V2 V5 modified moving average TWA TWA am 6 12 am 0 6 pm 6 12 pm TWA RVOT PVC LVOT QRS RVOT 36 6 msec LVOT msec p cutoff 27 msec RVOT PVC 4 anterior attachment posterior attachment free wall sep tumlvot PVC 2 LCC LCC RCC PVC PVC QRS PVC M TWA S BS A BS Controls HRV 24 6 pm 6 am 0 6 am 1 S BS V2 24 M TWA Control p S BS V2 M TWA 0 6 am Control A BS p V5 M TWA 4 HRV 0 6 am HF 5 S BS Vf S BS Vf M TWA V2 M TWA 0 6 am M TWA BS 7 6 AM
10 J Arrhythmia Vol 28 Suppl ICD ICD 69 3 V1 V2 ST T MRI ST narrow QRS V1, V2 coved ST 1 Holter 73 Holter Holter T
11 Brugada BRS BRS VFICD 7 EPS VF VF Brugada spontaneous Type 1 VF VF ICD SCN5A ICD VF VF VF spontaneous Type 1 VF P VF P ms 210 ms 210 ms 210 ms P J VF ICD J P P P BRS EPS VF J PQ vs ms V2 J ST vs mv time domain TWAEPS VF EPS VF SCN5A VF ICD VF 2 VF VF VF VF25 VF52 VF time domain TWA V vs V T wave shock VF20 CL SD vs ms VF VF ST PQ VFCL SD V2TWA VF 7 6 AM
12 J Arrhythmia Vol 28 Suppl 2012 Brugada IVF ERS ERS Brugada BrS ERS BrS VF ERS BrS EPS 3 VF ERS BrS EPS VF BrS ERS 75 vs. 48 p ERS VF 53 vs. 33 p 0.60 BrS VF 82 vs. 70 p VF BrS ERS 32 vs. 13 p 0.03 log rank test ERS BrS EPS VF VF ERS BrS VF Brugada Brugada BRS BRS AF ICD Brugada CA AF 19 AF AF 57 AF 6 AF AF P AF 73 4 AF 4 AF AF AF BRS CA AF AF AF AF
13 J epsilon Brugada 1 Brugada BrS J JWS J ECG V1 4 ST V1 V2 Brugada type1 J J ST QRS slur VF ST V2 J RR J V5 V6 QRS epsilon epw epw V2 J J J 1 52 I avl V5 V6 J Hz Activation recovery interval ARI QRS notch 12 J J ST VF 3 ECG ST V2 J ICD VF Qu 1 ECG J ST Qu VF ECG V5 6 epw Qu VF epsilon BrS JWS overlap V2 Br J J epw V2 J V5 6 epw V2 ST VF QRS notch ARI ms QRS notch ARI ms p N.S. ST ST ARI ST vs ms p J QRS notch 12 J QRS notch J QRS notch QRS notch QRS notch J QRS notch ARI ST ARI 7 6 AM
14 J Arrhythmia Vol 28 Suppl 2012 J J J J Brugada V5 1 mm J IVF 8 J C Holter SCM6000 Fukuda NASA CM5 J mm RR lnhf LF/ HF J RR J lnhf J LF/HF 1 IVF C 24 J/RR RR J J/RR slope mm/sec IVF C vs p 0.01 NASA CM5 2 J lnhf LF/HF J lnhf slope J LF/HF slope IVF C vs p vs p 0.01 J lnhf slope J LF/HF slope NASA CM5 3 IVF 7/ IVF J J 3 J J J J 12 J 0.1 mv J MC J QRS ST T J J 59 J J J ms J
15 J wave syndrome Tpeak Tend Tpeak Tend Tp e Tp e/qt ratio J wave syndrome J wave syndrome J 11 Brugada ERP C Synetec Holter analysis Software ELA Medical J wave J J J 5 ACh 69 J II III avf I avl V5 V6 2 J 1 mm QT QTc Tpeak Tend Tp e Tp e/qt one way ANOVA post hoc Tukey s test C ERP J QT QTc QT vs vs ms QTc vs vs ms Tp e Tp e/qt J ERP Tp e ms vs ms P Tp e/qt vs P 0.001C ERP Tp e vs P 0.97 Tp e/qt vs P 0.4 Tp e Tp e/qt J ERP Tp e Tp e/qt 69 ACh 41 VSA 28 control Ach J VSA control 28 2 VSA J P 0.01 VSA J 3 J 5 control 1 VSA J P diffuse type focal type J 13/30 1/11 P 0.05 diffuse type 3 spasm 7 5 J J 5/7 9/34 P spasm VF VSA diffuse spasm J substrate 7 6 AM
16 J Arrhythmia Vol 28 Suppl 2012 HCM AF HCM apical HCM apical HCM HCM apical HCM AF HCM 333 AF AF apical HCM172 apical HCM apical HCM 37 apical HCM 30 AF Kaplan Meier apical HCM 86 3 apical HCM apical HCM 77 4 apical HCM 68 6 AF AF BNP AF AF pg/ml p AF AF cm p egfr AF AF p BNP200 pg/ml OR3.1 p cm OR2.6 p OR2.2 p AF HCM AF 3apical HCM apical HCM BNP AF n n vs p Peak CK n n n n n 27 33n RR 3.47 CI p RR 3.69 CI p
17 17 QRS QRS I r 0.6 p III r P QRS POEMS 3 POEMS polyneuropathy organomegaly endocrinopathy M protein skin abnormalities POEMS CPR ST LVEF 65.0 vs p PVC burden I QRS III QRS PVC burden VA conduction beta p PVC burden beta P PVC burden POEMS 7 6 AM
18 J Arrhythmia Vol 28 Suppl head up tilt HUT BRS HUT HUT tilt table tilt 15 CT HUT BRS HUT BRS ms/mmhg p 0.01 BRS HUT BRS NMS PHP DC NC AP S A V A AP AP DC AP S A PS DC S A PS AP PS AP WPW 7 PHP DC NC pcs S A ms ms DC pcs 3 pcs pcs V A DC NC S A DC far field AP PS AP PHP DC S A PS PHP V A PS PHP NC DC S A
19 Kent A WPW 1 reentry 2 Atie Kent 23 Kent S1S1 500 ms 290 ms 280 ms Kent 55 ms 115 ms QRS WPW Kent Kent Kent longitudinal dissociation Atie Wellens WPW Kent JACC Kent antidromic block line WPW 1 spiky block line CS musculature Kent potential 7 6 PM narrow QRS regular 3
20 J Arrhythmia Vol 28 Suppl 2012 A WPW 2 15 kg 4 RFCA 3 RFCA kg RFCA ,852 g 9 22 II III avf V1 6 LVEF PSVT 288/min PSVT PSVT 44 RFCA EPS PFO AVRT TCL 208 ms RFCA max 28w 45 PSVT AVRT PFO WPW PFO RFCA 1 3 spontaneous automatic ity Sternick 3 PR QRS QRS P wide QRS QRS 240 bpm short RP ISP
21 AVNRT slow pathway potential SP TA Koch SP AVNRT EPS AVNRT P1 2 TA AVR 0.3 fragmented local poten tial FLP A 33 Slow Fast SF 25 Fast Slow FS 4 Slow Slow SS 4 AVR 0.3 SP B 10 SF 7 FS 2 SS 1 His EP Expert Doctors Team Tsuchiya His AVNRT AVNRT His AVNRT NavX 42 NavX Koch geometry Koch mapping /map His HBE Haissaguerre slow potential SP A vs. B 5 50 AVR A B vs P 0.01 A vs Hz P 0.05 B vs Hz NS A CS TA 10 mm mm vs. 45 P 0.05 SF FS 64 vs. 0 P 0.05 SF SS 64 vs. 100 NS Koch TA FLP SF SS AVNRT Koch TA Critical slow pathway most prominent SP HBE His HBE DHIS HIS 8 5 mm 0 25 mm His vs p Most prominent SP 1 AVNRT AVNRT His 7 6 PM
22 J Arrhythmia Vol 28 Suppl 2012 NavX Slow pathway EP Expert Doctors Team Tsuchiya AVNRT X slow pathway X NavX slow pathway AVNRT NavX 42 N 42 F N NavX Koch geometry Koch mapping /map His HBE Haissaguerre slow potential SP most prominent SP AVNRT N median 1 vs vs vs p N 11 4 F 21 3 NavX slow pathway / narrow QRS tachycardia 2 jump up sequence A H 180 msec 800 msec HIS 2
23 HR172bpm wide QRS tachycardia EPS ISP 2 jump up 265 msec His ATP HR 236 bpm narrow QRS tachycardia EPS ISP 2 jump up 292 msec His jump up smooth curve His 2 ATP trigger PM warming up triggered activity ATP10 mg trigger site
24 J Arrhythmia Vol 28 Suppl 2012 ATP ATP ATP AT ATP ATP AT EPS ATP AT ATP5 mg AA original AA EAS fragmentation 3D Electro Anatomical Mapping 3D EAM 1 EAS frag mentation 6 frag 5 frag 2 ATP fragfrag ms vs ms p D EAM 7 3 frag4 frag frag EAS low volt age zone ATP AT EAS EAS fragmentation ATP ms LAO 50 A B A B flecainide 1 1 n ms 19.2 ms ms 2 1 n ms ms p 0.013A n ms B n ms p A 240 ms 1 1
25 Low voltage zone EP Expert Doctors Team Tsuchiya Low voltage zone LVZ LVZ LVZ LVZ Ensite Array LVZ 17 8 contact voltage mapping 4 13 LVZ virtual activa in appropriate sinus tachycardia / long RP narrow QRS EPS long RP A sequence RV burst pacing tion map voltage map LVZ 15 contact activation map focal AT 9 reentrant AT 16 focal AT 12 LVZ 4 LVZ focal AT 9 re entrant AT LVZ LVZ channel Focal AT focus reentrant AT channel 17 5 LVZ reentrant AT LVZ channel Focal AT LVZ A sequence CARTO A A A warming up cooling down exit inappropri ate sinus tachycardia 100 mg/ in appropriate sinus tachycardia 7 6 PM
26 J Arrhythmia Vol 28 Suppl Fallot Ebstein 1 1 / / /9 89 3/4 75 2/ / / / / voltage map SVTCHD RFCA CARTO voltage map SVT RFCA EPS TOF 39 ASD 24 VSD 18 AVSD 3 Fon tan 4 Rastelli 2 Mustard 2 Senning EPS CARTO pacing voltage map 250 EPS SVT Typical AFL AT 34 typical AFL 30 AT AT 54 double potential RFCA SVT SVT SVT CARTO voltage map RFCA AT typical AFL
27 8mm tip Knuckle curve Ablaze CTI ABL large tip CTI ABL 8mm tip Knuckle curve Ablaze 8K 8 mm tip E cureve Ablaze 8E CTI ABL 354 CTI ABL 52 8 mm tip Knuckle curve K mm tip E curve E EPS 12 ECG bpm narrow QRS tachy cardia avf avl P AT EPS AT1 P 43 msec 50 20W AT1 avf P AT1 avl I 35W W CTI ABL K K vs E vs I 100 vs 98 vs 93 P 0.05 K P I 1 8 mm tip Knuckle curve 8 mm tip E cureve AT2 2 AT1 AT1 AT1 Bump AT1 AT W AT1 AT2 20 msec AT2 AT AT 7 6 PM
28 J Arrhythmia Vol 28 Suppl IAS IAS mm EEPVI TCL 255 ms regular P avf V1 LA post pacing interval PPI TCL RA activation mapping IAS centrifugal pattern spiky near field RA far field LA dull double potentials DP A PPI TCL RA LA EEPVI IAS RA dull spiky A P 116 ms B EEPVI IAS AT IAS breakthrough RA LA 1 RA AT 2 IAS IAS DP DDD Identity DR, St. Jude Medical AF burden 12 BNP AF burden 0.4 vs. 2.1 P BNP 53.8 pg/ml vs pg/ml p AF burden
29 AFL/AF QOL AF / AT/AFL ATP AT/AFL ATP Medtronic ADVISA DR AT/AFL Medtronic ADVISA DR 117 AT/AFL ATP therapy on AF burden LAD LVDd/Ds LVEF AT/AFL 960 ATP ATP therapy 1. burst rump ATP AT/AFL mm 10 ATP AT/AFL 50 5 ATP ATP therapy A n 90 S n vs p vs mm p vs ma p vs p A vs V p S vs p 0.95 Mode switch A 28 31S AF burden vs p 0.41 HR CI p PM
30 J Arrhythmia Vol 28 Suppl 2012 AVB PM AVB SSS AVB PM / 9.1 SSS AVB 6 ApAVB Ap 20 Ap 20 AVB Ap 20 SSS 39.8 vs 87.1 p AVB 10.8 Ap Ap 80 AVB Ap 20 Ap 20 Ap / 5.5 vs 42.0 / 6.9 mm p / 14.3 vs 82.9 / 13.7 bpm p vs 46 p / 2.4 vs 58.8 / 3.3 bpm p OR CI p OR CI p OR CI p Ap 20 SSS AVB AVB 1 Therapeutic Research, EPS 5 AAIR 1.6 V 0.4 ms V 0.37 ms / 1.2 V / / 1.2 V 0.4 ms 80/ 40 50/ 2.8 V 0.4 ms P 1000 ms 60/ 10 4
31 LVEF LVEF LVEF V QRS LVEF p QRS LVEF msec msec p LVEF QRS VVI 6 follow up X p RA L CT TA L TA Ap TL/TAp V X p RA L mm vs mm p 0.02 CT TA L 27 8 mm vs 41 9 mm p 0.01 TL/TAp vs p TL/TAp cut off PM
32 J Arrhythmia Vol 28 Suppl SP 2 SP RVA 186 SP 101 QRS RVA ms SP ms RVA FW FW AS PS OPS RVO RVM CT 64 TT RVO RVM RVM 37 OPS 20 AS 16 FW 1 3 RVO 27 PS 5 PS AS OPS 1 AS 12 FW 9 4 RVM OPS QRS ms RVM OPS QRS I A mp mv RVO PS RVM AS P RVO AS P RVO FW P 0.001RVM OPS 0/20 RVO PS 0/5 RVM AS 4/16 P 0.05 RVO AS 6/12 P 0.01 RVO FW 5/9 P 0.01 S RVM OPS 12/20 RVM AS 7/16 RVM 20/37RVO 5/27 P 0.01 QRS RVM OPS RVM AS P OPS TT I A mp 0.3 mv PPV69 NPV100 I Amp 0.6 mv PPV87 NPV68 RVM OPS QRS I QRS S
33 / 7.9 X CT CT 11 N 10 L Cardiac Contrac tion Map Maine Inc., Kobe 8000 max contraction max con tradiction phasedelay algorism RR X 8.3 vs 66.7 p CTR 58 / 5.6 vs 53.7 / 4.8 p / 10.9 vs 40.3 / 15.1 mm p 0.03 QRS / 18.1 vs / 19.5 ms p QRS I 0.5 / 0.2 vs 0.2 / 0.3 mv p avf 0.2 / 1.1 vs 0.7 / 1 mv p p / I QRS QRS CTR duration of contraction SDCLBBB max contraction N vs. L vs p max contraction phase vs p 0.05 duration of contraction vs SD p 0.05 CT Cardiac Contraction Map CT 7 6 PM
34 J Arrhythmia Vol 28 Suppl 2012 CRT 30 non responder 2 CRT 1 3 non responder CRT EPS CRT NYHA II IV QRS 120 ms EF 35 CRT 52 CRT EPS LV dp/dt LV dp/dt CRT CRT6 LVESV EPS LV dp/dt EPS LV dp/dt EPS CRT 6 LVESV ml vs ml p ml vs ml p EPS LV dp/dt CRT6 LVESV r p r p r p CRT EPS LV dp/dt reverse remodeling CRT 17 CHD CRT CHD CRT dyssynchrony CRT CHD17 11 ctga 6 2 Responder NYHA EF ctga p ctga 3 50 Upgrade 4 36 DDD ctga 4 67 VVI AF DDD LV CRT CRT D 2 1 Responder cTGA3 50 p NYHA ctga p EF 14.2 ctga 2.6p 0.08QRS 10 msec ctga 17 msec p 0.5 CHD CRT
35 CRT RFCA SA CRT HT CRT 138 SR 75 SA HT SA HT 10 SA CRT SA SR 3 SA HT 0 SA 6 SR SA HT CRT CRT CRT VT transmural dispersion of reporal ization TDR CRT CRT P26 CRT D TDR 12 V1 V6Tpeak endt CRT SA responder SR 57 SA HT 70 SA 65SR HT SR NHYA SA HT SA BNP SA HT SA CRT CRT CRT CRT VT VT QRS QT QTc QTd Tpeak end VT CRT 3 P 0.05 Tpeak end CRT 3 CRT VT P 0.05 CRT TDR 7 6 PM
36 J Arrhythmia Vol 28 Suppl 2012 ICD ICD ICD ICD ICD ICD ICD ICD VF ICD 10 ICD ICD ICD 30 VF 5 J 9 5 J VF J 270 J 27 5 J VF 3 5 J ICD ICD ICD ICD ICD LVEF LVEF45 25 ICD ICD LVEF modi fied Simpson GSRIVR 2D 3 EchoPAC PC GE ICD 5 4 ICD LVEF ICD LVEF p ns LVEF 5 4 p 0.05 GSRIVR 5 4 both p 0.05 ICD LVEF p 0.05 LVEF ICD LVEF
37 BNP CIEDs Preclinical BNP OptiVol CIEDs BNP OptiVol CIEDs EF ICD 17 CRTD 83 BNP Optivol MEDTRONIK Carelink Optivol ICD/CRT D 83 Optivol data BNP r 0.36 p r p 0.05 CIEDs ICD/CRT D LVEF Optivol Index Optivol Index A n 7 Optivol B n 34 LVEF A LVEF 35 PARTNERS HF J Am Coll Cardiol PM
38 J Arrhythmia Vol 28 Suppl 2012 OptiVol OptiVol Fluid Index Medtronic CareLink Network CL OptiVol QOL Medtronic ICD CRT D ICD 54 CRT D 46 LVEF 36 14OptiVol 1.0 OptiVol OptiVol Fluid Index OVFI OVFI 30 X BNP OptiVol OptiVol OVFI P OVFI P OVFI OVFI P ROM OVFI Cut off 130 AUC OptiVol 1.0 OptiVol OVFI CE MRI Delayed Image VT MRI CE MRI VT 15 VT 15 CE MRI CE MRI Q Mass MR software Me dis medical imaging system non viable viable signal index SI 3 standard deviation SD 3 SD SI 2 SD VT VT CE MRI
39 QRS 1 12 Selvester QRS QRS OMI SAECG OMI MCG SAECG OMI LVEF ARVC 25 MCGSAECG SAECG ARVC 9 24 QRS Selvester II III LVEF vs p QRS vs p QRS AUC 0.77 QRS OMI CRBBB IVCD MCG ARVC OMI CRBBB IVCD OMI ms 51 7 ms p OMI SAECG 1 4 SAECG 7 OMI MCG SAECG 7 6 PM
40 J Arrhythmia Vol 28 Suppl 2012 late potential LP LP SCM8000 VT 11 VT VT 12 VT QRS fqrs ms RMS40 V LAS40 ms LP 6 fqrs LAS40 VT VT RMS40 VT f QRS RMS40 VT fqrs LAS40 RMS VT VT VT LP ARVC SAECG LP VT ARVC EPS DP46 SAECG LP ARVC EPS VT DP SAECG SAECG 3 fqrs 120 ms RMS40 18 V LAS40 38 ms 2 LP EPS DP 3D LP EPS DP 100 DP DP RV 8 22 DP 2 5 p 0.01 EPS VT VT VT DP ARVC DP SAECG LP ARVC
41 Fragmented QRS 12 Fragment ed QRS fqrs EPS 1 ICD fqrs ICD 66 EPS 13 fqrs 2 35 Cardiac resynchronization therapy CRT left ventricle ejec tion fraction LVEF 35 LVEF 35 CRT CRT QRS msec LVEF / 16/5 NYHA II/III 9/13 / 15/7 LVEF /7/1 fqrs non fqrs 53 fqrs n 18 non fqrs n vs p NS NYHA class vs p NS egfr vs p NS ICD 6 11 Non fqrs Kaplan Meier fqrs EPS fqrs 22 LVdP/dt CRT 1 NYHA BNP pg/ml vs pg/ml p 0.02 LVEF vs p mm vs mm p /1/ NYHA LVEF 35 LVEF 35 CRT QOL CRT PM
42 J Arrhythmia Vol 28 Suppl 2012 ATTEND registry ATTEND registry Steering Committee JCS2011 ICD IIaSCD HeFT SCD HeFT ICD ATTEND registry NYHA II III LVEF ICD n 34 ICD control n vs. 7.7 p Fig.1 ICD control 33.0 vs p Fig.2 ATTEND registry SCD HeFT ICD ICD 2010 HRS Expert consensus ICD ICD 2012 ICD ICD pacing 1 2 ICD ADL ADL ICD ICD
43 AED AED 30 AED 9100 AED AED AED AED RM EVENTS RM ICD CRT D RM CareLink network system Merlin. AED AED AED AED AED AED AED net system RM EVENTS EVENTS RM 9 5 RM 89.1 RM RM P 0.001EVENTS RM RM EVENTS RM RM P RM EVENTS EVENTS 7 6 PM
44 J Arrhythmia Vol 28 Suppl / RMS RMS RMS RMS 165RMS 1 RMS 2 RMS 3 RMS RMS 2 RMS 3 RMS RMS
45 RMSRMS RMS RMS RMS 1, RMS RMS Medtronic Carelink RMS SJM Merlin. net RMS RMS n 23 RMS n vs p RMS 2 5 RMS Merlin.net RMS 7 6 PM
46 J Arrhythmia Vol 28 Suppl 2012 ICD/CRT Abdel Shafee Mohamed CRT/ICD 6 ICD/CRT 189 ICD/CRT D n CRT D/P n 74 ICD/CRT D n vs / P vs / P vs / P 0.05 CRT D/P n vs / P BNP vs pg/ml P vs. 80 P vs / 5 P 0.05 ICD/CRT ICD CRT 170 Remote vs Non Remote Remote Non Remote 2 Remote 22 Non Remote 8 Remote Non Remote Remote P 0.05 Remote Non Remote Remote P 0.05
47 SVC CRT D 1 ICD SVC 180 RM RM 50 High Voltage Device HV RM 250 HV 150 Pacemaker PM 100 RM 1 RM 2 3 RM CRT D AC CRT D Lumax 540 HF T, Biotronik SE & Co.KG, Berlin, Germany Linox SD, Biotronik SE & Co.KG, Berlin, Ger many RV SVC 100 SVC 76 SVC SVC SVC RM RM RM 66HV 81.2 PM RM HV RM RM PM HV RM HV HV RM 7 6 PM
48 J Arrhythmia Vol 28 Suppl 2012 Pacemaker pocket infection Pacemaker pocket infection Pacemaker pocket infection 52 device erosion Pacemaker pocket infection lead extraction lead extraction P P CRP P P lead extraction lead extraction 11 P pacemaker pocket infec tion lead extraction lead ex traction mortality lead extraction AF voltage AF 117 AF 30.4 AF Isoprot erenol AF NaVX velosity one map voltage map PV AF Non PV 63 PV vs. 26 p AVNRT 3 SNRT vs ml p AF 45 vs. 27 p vs. 32 p voltage mapping AF
49 CFAE AF ABL com plex fractionated atrial electrogram CFAE ABL 3 AF ABL ABL 3 AF ABL 3 6 BNP ABL 8 Dominant frequency culprit rotor Dominant frequency DF DF , NavX 8 Hz high DF fractionated interval FI 50 ms continuous complex fractionated atrial electrograms CFAEs 45 CFAE ABL ABL mm vs mm P mm p E/e vs p 0.01 A ABL cm/s vs cm/s p cm/ s p 0.01 BNP ABL pg/ ml vs pg/ml P pg/ml p AF ABL 3 CFAEs DF FI CFAEs DF high DF CFAEs high DF overlap DF high DF vs. 59 P vs. 22 P CFAEs DF DF high DF continuous CFAEs AM
50 J Arrhythmia Vol 28 Suppl 2012 AT EEPVI Roof line R 6 EEPVIPLA I 34 EEPVI PLA I MI 40 R 2 33 PLA I PLA I MI R 83 PLA I 88 PLA I MI EEPVI R 1 17PLA I 1 3PLA I MI AT AT PV 6 Focal AT 2 1 AT 1 1 PLA MI AT MI 1 MI AT 10 AT mm /
51 ATP ATP 6 57 ATP 54 2 Ex 12 3 ganglionated plexus GP complex fractionated atrial elec trogram CFAE En Site CFAE map pre CFAE 5 GP CFAE map post CFAE 24 GP CFAE area N 42 Ex Ex Ensite NavX 1 beat Ex 7/ N 8/ Ex Ex 7 N 8 2 pre CFAE GP SLGP 96.7 point 5 Mar shall GP LIGP 77.0 point 4 ARGP 93.4 point 4 IRGP 73.8 point 2 GP post CFAE area pre CFAE area post CFAE area P.0001 pre CFAE GP area GP CFAE GP CFAE 7 7 AM
52 J Arrhythmia Vol 28 Suppl 2012 Ganglionated Plexus Ganglionated Plexus GP EEPVI EnSite NavX Geometry GP CL50 msec 30 ma 10 msec Vagal Re sponse GP Map GP Superior Left GP SLGP Marshall GP MAGP Anterior right GP ARGP Inferior left GP ILGP Inferior right GP IRGP 5 EEPVI GP SLGP MAGP ARGP GP ILGP IRGP GP GP SLGP MAGP ARGP ILGP IRGP ARGP GP 179/ EEPVI GP 9/105 9 EEPVI P EEPVI GP GP GP EEPVI GP Gaglionated Plexi Gaglionated plexi GP PAF PAF RFA GP RFA PV PAF PV PVI PVI HFS PR GP HFS SLGP LIGPPLA ARGP GP RIGP GP HFSPR RFA AF LS/RSPV 20 CS Dominant frequency DF CL GP RFA 1,105 HFS / HFS GP / GP PR 66.6 HFS and 59 NS SL/ ILGP PLA RFA PV DF LSPV vs Hz RSPV vs P 0.05 CS vs Hz P 0.01 CS LSPV CL LSPV vs CS vs p 0.05 RSPV vs ms NS AR/ IRGP RFA RSPV DF RSPV P 0.01 LSPV P 0.1 CS Hz NS LS/RSPV CS CL LSPV NS RSVP ms CS ms P 0.1 HFS GP PR GP RFA GP RFA PV PAF
53 Ganglionated Plexi LGE MRI CARMA Center Akkaya Mehmet Blauer Joshua J.E. Burgon Nathan S. Damal Kavitha Cates Joshua Kholmovski Eugene MacLeod Rob S. Marrouche Nassir F. AF PVI ganglionated plexi GP GP FP PVI ABL 60 3 ABL lesion scar LGE MRI ABL GP area FP T 2 segment 3 D Figure A FP LGE MRI PAf 35 CAF 32 LAESVLAEF LVEF CAF LVEF 50 8 low EF N EF LAEF LAESV LVEF CAF LAEF p 0.01 LAESV ml p 0.05 LVEF PVI scar Figure BScar FP ABL FP Figure C ABL FP area AF vs P 0.02 Figure D PVI SDNN ABL FP area P 0.03 Figure E LGE MRI ABL FP area GP area ABL AF p 0.05 LAEF 3 LAEF PAF LAEF LAESV ml LVEF p ns PAF CAF LAEF CAF LAEF PAF vs CAF vs p 0.01 CAF low EF LVEF LAEF low EF vs N EF LVEF vs p 0.01 LAEF vs p 0.07 CAF LAEF/LVEF/ LAESV PAF CAF low EF LVEF LAEF 7 7 AM
54 J Arrhythmia Vol 28 Suppl Left ventricular ejection fraction LVEF 50 EF n LVEF 50 EF n linear ablation LVEF EF EF Left atrial volume index LAVI E/E 3 EF EF 21.4 LVEF EF P EF LAVI ml/m ml/m 2 IIb AF MR MR AF CA MR MR jet area 20 significant MR AF significant MR CA3 MR jet area coaptation length MDCT MR MR jet area 10 trace CA MR 1 Significant MR 26 MR jet area 31 / 9 18 / 11 CA 3 MR 2 MR vs. 83 p vs. 56 p CA 3 36 / 28 vs. 10 / 24 p / 10 vs. 12 / 9 p coaptation length 66 / 56 vs. 9 / 29 p MR 2 / 6 vs. 1 / 3 p 0.20 MR CA
55 fractionation Dominant frequency DF paroxysmal AF 27 nonparoxysmal AF NavX fractionation complex fractionated atrial electrograms CFAEs Fractionated interval FI ms LA P RA P rapid activation AF CA AF CA AF AF CA 70 CA 3 64 MDCT / RAEDVI / LAEDVI 3 RAEDVI RAEDVI 3 LAEDVI LAEDVI 16 7 continuous CFAEs FI 50 ms LA P RA P mean DF LA P RA P mean FI ms vs ms P 0.001nonparoxysmal AF CFAEs mean DF 8Hz high DF CFAEs high DF overlap DF 36 1 continuous CFAEs high DF continuous CFAEs bottom high DF cavo tricuspid isthmus CFAEs DF AF 3 CA3 LAEDVI RAEDVI LAEDVI to ml/m2 p 0.01 RAEDVI to ml/m2 p 0.01 LAEDVI 20 n 35 LAEDVI 20 n vs. 49 p LAEDVI 35 ml/m2 n ml/m2 n vs. 47 p 0.05 RAEDVI 20 n 28RAEDVI 45 ml/m2 n 18 AF 29 vs. 43 and 28 vs. 40 p 0.23 and 0.34 respectively AF CA CA 7 7 AM
56 J Arrhythmia Vol 28 Suppl 2012 HemoclotTT aptt ACT HemoclotTT HemoclotTT aptt ACT egfr65 17 ml/min/1.73 m 2 HemoclotTT aptt ACT 6 HemoclotTT egfr HemoclotTT aptt ACT HemoclotTT g/ml ACT aptt vs vs p 0.01 egfr 60 ml/min/1.73 m 2 vs vs p 0.02 ACT r 0.87 p aptt r 0.69 p ACT 3 aptt 80 aptt aptt 107 aptt retrospective 107 aptt mg/ aptt CCr p mg/ 70 aptt CCr p aptt p vs aptt CCr p 0.001aPTT aptt vs CCr aptt
57 AIT AIT AIT 71 AIT 5 7 AIT IKr E 4031 IKr IKr E 4031 dofetilide nifekalant se matilide amiodarone 10 kg 1 His MAP AIT AIH 100 vs 16 P vs P g vs g P AIT AIH 5 AIT 7 AIH AIT 400 ms MAP90 ERP E mg/kg 0.1 mg/kg n 4 E mg/kg QT/QTc MAP90 ERP E 4031 QT/QTc MAP90 ERP dofetilide nifekalant sematilide amio darone IKr 7 7 AM
58 J Arrhythmia Vol 28 Suppl 2012 CBX n mm BDM mm200 nm 1 mm 1 mm M CBX m/s mm CBX CBX CBX Cardiac Morphology Unit, Royal Brompton Hospital, National Heart and Lung Institute, Imperial College London Koch compact node Koch 100 m ScanScope Aperio ImageScope Aperio 3 A 6 B 6 C 9 B mm P mm P
59 photodynamic therapy PDT PDT cavo tricuspid isthmus line CTI kg Fr Scroll Wave AF PtAF 3 Scroll Wave SW PtAF SW 20 Hz PtAF AF n 8 12 cmh2o AF 610 mw 2.5 mg/kg mw CTI PtAF n 5 PtAF SW I AF 74 70SW 12SW PtAF vs sec p 0.05 SW SW PtAF vs mm p 0.05 PtAF 3 PtAF SW SW 7 7 AM
60 J Arrhythmia Vol 28 Suppl 2012 gap junc tion family channel GJC ATP C 57 BL/6 J TAC TAC Cytometric bead array TAC GJC carbenoxolone GJC F4/80 TAC 1 TAC 5 IL 1 IL 1 IL 6 MCP 1 Mallory Azan Carbenoxolone TAC GJC ATII 1 8 C57BL/6 CNT ob/ob ob ATII 2.0 mg/kg/day VEH 2 AF Masson Trichrome RT PCR mrna 2 Sprague Dawley ATII 24 1 CNT ATII 87.5 AF ob ATII 0 p 0.01 CNT ATII ob ATII SMA 1 MCP 1 mrna p 0.01CNT ATII VEH mrna p ATII p 0.01 SMA MCP 1 p 0.01 ATII
61 CT CARTO Merge tion 6.72 mm mm Surface Registration 1.44 mm mm CT Seg mentation Registration Segmentation Ultrasound SOUND MERGE Device CT Merge CARTO Merge CT 3 CT CARTO Merge CT CARTO Import Segmentation Landmark Registration Surface Registration CT CARTO Merge 4 Landmark Registra CARTO SOUND CARTO MERGE CARTO 3 system point map ping PM MERGE Fast Anatomical Mapping FAM MERGE CARTO SOUND system MERGE CARTO 3 system PM FAM CARTO SOUND mapping PM FAM LPV LIPV Landmark Surface Registration LPV MERGE LPVI RPV Surface Registration RPV MARGE 2. CARTO SOUND map ping 3 LPV LIPV Landmark LPV MERGE 1. PV PM FAM CARTO SOUND mapping MERGE 3 DCT Match View MAGRGE PV MARGE 3DCT mm MERGE PM mm FAM mm CARTO SOUND mapping mm point mapping CARTO SOUND mapping PM CARTO SOUND mapping p FAM p PM FAM MERGE CARTO SOUND system MERGE CARTO SOUND map ping MERGE PM MERGE 7 7 AM
62 J Arrhythmia Vol 28 Suppl 2012 CARTOSOUND mean SD pouch mm eustachian valve 5 TA IVC isthmus CARTOSOUND TA IVC isthmus Eustachian valve pouch CARTOSOUND Biosense Webster, Diamond Bar, CA, USATA IVC isthmus CARTOSOUND 7 CARTOSOUND eustachian valve TA IVC isthmus pouch Isthmus mm CARTO SOUND Contour CARTO MERGE AF CARTO SOUND CARTO CT CARTO electroanatomical EA CT CARTO SOUND CT AF 17 AF EA 40 5 EA MERGE CARTO SOUND 10 2 Contour SOUND MERGE CT surface registration 3 1 visual alignment CT surface registration program EA MERGE CT mm 0.06 mm 3.81 mm SOUND MERGE mm 0.03 mm 4.03 mm EA MERGE EA MERGE SOUND MERGE p 0.05 CARTO SOUND CT EA CARTO SOUND CT AF
63 CARTOSOUND 3 D AF 3 D AF CARTO Version CARTO Xp Xp CARTO 3 C 3 CARTO SOUND SOUND 3 variant Aorto mitral Continuity variant variant 50 Aorto mitral Continuityn 3 n 8 n 32 n 2 Aorto mitral Conti nuity monophasic R wave 94 V6 Rs pattern AF Xp Land mark Surface Registration CARTOMERGE C 3 Fast Anatomical Map CARTOMERGE FAMergeSOUND SOUNDMERGE Xp C 3 Xp vs. C vs min p SOUND C 3 vs. SOUND vs min p Xp vs. C 3 vs. SOUND vs vs mgv p vs vs ml p D SOUND 65 V1 V4 1 V6 S wave Intrinsicoid deflection time IDT Aorto mitral Continuity p 0.05 IDT 85 ms R perfectmap near perfect map QRS ms 76 prepotential V2 R V6 S wave AIV pacemap 12 QRS 7 7 PM
64 J Arrhythmia Vol 28 Suppl Cusp group n 20LV group n V2 Cusp group 3 15LV group 9 64 R wave duration index R/S wave amplitude index LV group Cusp group V5 6 S LV group 6 43Cusp group 1 5LV group Cusp group I S avl Q /avr Q 2. activation map ping pace mapping Cusp group good pace map LV group good pace map p 0.01 Aortomitral continuity II R III/II avl avr Q avl/avr maximum deflection index MDI I RS pattern I R S R/S I R notch dull pattern AMC 12 ECG Aortomitral continuity AMC N / 3 12 ECG V3 V1 3 V3 1 III
65 VT VT VT optimal result VT strategy 12 VT OMI VT 48 VT mapping mid diastolic potential pace map clinical VT VT VT optimal result VT ms VT Activation map Pace map VT VT 11 Substrate VT VT 11 ICD 8 7 I VT 9 59 ICD pace map non clini cal VT sub optimal result VT sustained VT ICD shock optimal result 23 sub optimal result 25 EF Optimal re sult 22/23 95 sub optimal 14/25 56 VT p p NSOMI VT Optimal result sub optimal result 7 7 PM
66 J Arrhythmia Vol 28 Suppl 2012 CHADS2 CHA2DS2 VASc STACIN CHADS2 CHA2DS2 VASc / CHADS CHA2DS2 VASc HAS BLED CHADS2 CHA2DS2 VASc vs P vs P 0.03 AUC CHADS2 CHA2DS2 VASc HAS BLED r 0.63 P r 0.47 P CHA2DS2 VASc 0 1 / 4 CHADS2 CHA2DS2 VASc CHADS2 CHA2DS2 VASc CHADS2 J ROCK ET AF J ROCKET AF Xa RIV WAR RIV WAR WAR RIV CHADS /year RIV WAR p RIV WAR HR CI p HR 95 CI P RIV HR CHADS2
67 AF AF AF AF 116 Group AF89 CHADS INR 117 Group AF56 CHADS INR AF Tachycardia induced cardiomyopathy TICAF AFL TIC n 15, TIC 1 AF AFL HR 100bpm LVEF EF TIC AF AFL mg/ mg/ 5, ACT 300 Group1 30 Group2 29 MRI Group1 4 1 Mallory Weiss 1 6 Group vs. 14 p 0.05 MRI BMI BNP LVEF CHADS2 score TIC CHADS2 score TIC 7 7 PM
68 J Arrhythmia Vol 28 Suppl egfr 4 no/ mild CKD egfr 60 ml/min/ n CKD stage ml/min/ n CKD stage L/min/ n CKD stage 5 15 ml/min/ n Hb 2 g/dl 2 1 HAS BLED score Cre 200 mol/l egfr 60 L/min/ HAS BLED score CKDstage3 5 no/ mild CKD all P HAS BLED score HAS BLED score 0.65 vs 0.70 P II II ARBPAF 12 PAF PAF PAF ARB PAF ARB/ACE I 3 PAF 3 PAF 57 3 PAF mg/day 19 PAF PAF p 0.02 PAF PAF
69 1 B A P AF A B 40 P AF 3 A 35 B 85 p 0.05 A 50 B 75 QT B torsade de pointes B amiodarone amio darone amiodarone amiodarone CPK IABP 50 vs 10 p PCPS 21 vs 2 p amio darone 7 7 PM
70 J Arrhythmia Vol 28 Suppl 2012 VT VF AMD NIF 2 2 CPA AMD NIF CPA VT/VF AMD NIF ROSC AMD NIF mg mg VT/VF by stander AMD p 0.06 ph p 0.06 ROSC AMD 73 NIF 82 p 0.56AMD 42 NIF 36 p 0.56NIF AMD ROSC p p 0.04NIF AMD 27 8 p 0.13 PEA 7 21 p 0.20 VT AMD p 0.01 VF p 0.52 AMD NIF 2 ROSC VT NIF AMD VF QT mg/ 3 30 Cre 0.75 mg/dl K 4.3 meq/l CT 53/ QT 550 ms U 2 V2 V6 T U QTU 720 ms QT 520 ms V4 V6 QTU 640 ms V2 V3 0.1 g/ Kg T V2 V5 QTU T QT 20 mg/ T KCNH2 T1083fs/33X type2 QT C
71 ICD CRTD ICD CRTD Brugada QT ES ICD 252 ES ES ES ES NYHA class Hazard ratio HR CI I I HR CI VT Brugada vs p p Kaplan Meier p Kaplan Meier p Brugada 2 HR CI ES III CA ES CA CA 16 VT/ VF 4 25 ES EF35 HR CI ES III CA VT/VF ES III VT I ES VT CA ES ES 7 7 PM
72 J Arrhythmia Vol 28 Suppl 2012 ES CA CA ES CA ES CA VT VF PVC 3 LP 3 PVC 3 3 PVC 2 ES PVC ES 1 1 ES ES PVC ES ES VT/VF ES electrical storm 2 electrical storm CTO 8 HR 140 bpm 19 mid diastolic potential concealed entrainment 2 59 IgA II III avf V 5 6 ST CTO VPC 7 VPC Pace map VPC QRS 44 ms VPC
73 CPVT PVT VF CPVT blocker ICD electrical storm CPVT CPVT OSA RFCA OSA CPAP RFCA RFCA RFCA1 AHI 5 CPAP VPC PVT CPVT 6 isoproterenol epinephrine 2 VPC PVT VPC PVT 11 n 3 27n 2 18 n 3 27 n 2 18 n 1 9 VT PVT VF CPVT VF PVT trigger VPC PVT PVT VF ICD No OSA Gr nasal CPAP CPAP Gr No CPAP Gr No CPAP Gr 51 CPAP Gr 27 No OSA Gr 24 P by log rank test Cox HR CI p 0.05 OSA HR CI p 0.05 CPAP HR CI p 0.05 No OSA Gr No CPAP Gr ROC AHI 10 OSA RFCA AUC 0.69 p 0.01 OSA RFCA CPAP RFCA OSA RFCA CPAP 7 7 PM
74 J Arrhythmia Vol 28 Suppl 2012 EP Expert Doctors Team Tsuchiya CS CS CS NavX mlcs 3DCT EnSite NavX segmentation soft ware Verismo version 2.0 CS CS 2 mm CS 20 9 mm 18 9 mm range 4 43 mm r 0.52 p CS 80 CS cc VS p VS p VS p p p
75 SensiTherm ME PVI ESO SensiTherm ST. Jude Medical ESO SensiTherm ESO ESO PVI ESO ESO SensiTherm Sensi domi nant frequency PV dominant fre quency DF 4.8 Hz PV AF PV culprit PV AF AF PV bystander PV DF AF PV AF 27 PV DF 5 6 culprit PV DF mean DF DF highest DF mean DF culprit PV m culprit PV highest DF culprit PV h culprit deflectable ABL A ABL A Sensi Sensi S ABL S T Sensi T ABL mm Sensi S ABL S mm A ABL T ABL T Sensi P A Sensi T ABL T Sensi P PVI SensiTherm ESO PV culprit PV AF m culprit PV LSPV 9 LIPV 9 RSPV 6 RIPV 3 DF Hz h culprit PV LSPV 8 LIPV 9 RSPV 5 RIPV 5 AF PV m culprit PV h culprit PV 44.4 m culprit PV 7 26h culprit PV 11 41AF bystander PV 14 DF culprit PV by stander PV mean DF p highest DF p bystander PV DF cul prit PV AF PV AF DF PV AF 7 7 PM
76 J Arrhythmia Vol 28 Suppl egfr 60 ml/min/ 1.73 m ml digital subtraction angiography DSA egfr ml/min/1.73 m ml/ min/1.73 m2 P 0.74 N.S 3 egfr 42.2 ml/min/1.73 m ml/min/1.73 m2 p 0.52 N.S 3D CT 3D CT 3D CT cm 3D body mass index BMI mm BMI r mm
77 A 5 9 B C GLPS electro physiological study EPS SD SD kg AP AVNRT EAT 9 5 VT/ PVC 7 4 JET 5 3 IART 7 4 unknown SVT SD SD / / A B C p B C RVA RVMSRVOT 3 GLPS RVOT RVMS RVA GLPS RVMS 14.1 vs 13.2 p RVA 14.1 vs 12.6 p RVMS RVA GLPS 13.2 vs 12.6 p PM
78 J Arrhythmia Vol 28 Suppl 2012 Electrosurgical dissection system Electrosurgical dissection system EDS COOK USA 2009 Excimer laser system ELS Non functional lead 26 Ma jor complication complete success partial success EDS PSA PM/ICD Pace MakerPM /Implantable Car dioverter Defibrillator ICD Pacing System Analyzer PSA PM/ICD PSA PM/ ICD Medtronic PM/ICD 27 Advisa DR 17 Protecta XT DR 9 Protec ta XT CRT D 1 P 21 R 21 Medtronic 2090 PSA 2290 Pacing PM/ICD 3 P PSA mv PM/ICD mv p V 0 8 R PSA mv PM/ICD mv p V 1 13 PM/ICD A/V PSA PM/ ICD PSA 1
79 SJM Optisense Far field R wave FFRW FFRW oversensing CIEDs Blanking CIEDs CIEDs 1.1 mm FFRW SJM Optisense 10 mm FFRW CIEDs BARD LabSystem stamp CRTLV RV IB TB RV/LV V V CRT IB TB CRT D 26 TB n 16 IB n 10 LV LV 1 RV Op tisense 1.1 mm 16 Standard 10 mm 8 P FFRW LabSystem Optisense OPStandard ST P OP mv ST mv P 0.92 FFRW OP mv ST mv P 0.01 P FFRW FFRW/P OP ST P FFRW Optisense P FFWR P FFRW OP FFWR oversensing LV RV IB RV 2 RV LV RV LV RV LV RV LV RV LV V vs V p LV RV V V V LV LV 7 LV RV 19 RV CRT RV TB IB 7 7 PM
80 J Arrhythmia Vol 28 Suppl 2012 ICD PhD ICD ICD Guidant Prizm2 DR 1861 Sorin Paradym DR 8550 DDD ICD non sustained VT mv ON ICD PhD OFF Paradym PhD ICD in tegrated bipolar Riata ICD Riata SJM tip 2 coil 1 ring Riata ICD X Xp ICD Atras SJM R mv V Xp Xp R mv 2.0 mv T oversensing ICD Xp 1 R ICD Durata SJM Riata 2/10 1 R T over sensisg Riata Xp
I PD-I-3 VA ICD 2006 NYHA ~ LVEF 35% a ICD SCD-HeFT ICD MADIT- ICD a CABG-Patch ICD EF b MADITø MADIT- MUSTT EPS EPS 19 EPS 5/19 VA PD-I-4 Holter LP f
J Arrhythmia Vol 23 (Suppl) 2007 PD-I-1 OACIS 95% 6.4 (1.5 27.8 4.3 (1.0 18.5), 0.2 (0.05 0.93), respectively MADIT LVEF 30% 192 2.0 12.4% 24 3.1% MADIT 12.1% p=.001), ICD direct PCI OACIS (Osaka Acute
22...J.e.A.u.Q01-07_.O.t
113:00~14:00 The Value of Electrogram Analyses in Defining Arrhythmia Mechanisms-Implications for Catheter Ablation Melvin M. Scheinman University of California San Francisco, USA 1 112:00~13:00 Next Generation
P. 1 P9. Introducer P10. ) ) 2 P11. 1 P12. polytetrafluoroethylene 1 P13. P14. P15. 1 P16. twiddler syndrome 1 P1. h 141
) ) A 1 ) ) P1. AAI ME P2. DDD MR HOCM 1 P3. middle cardiac vein P4. MRSA P5. ) P6. 319 1 P. 1 14:30 15:30 140 P. 1 P9. Introducer P10. ) ) 2 P11. 1 P12. polytetrafluoroethylene 1 P13. P14. P15. 1 P16.
098青沼班DGfinal修正0506.indd
1 2011 Brugada QT 2005 2006 2007 Brugada Brugada 20 QT 70 2007 Brugada ICD ICD 5 2 QT Brugada 2012 QT QT QT Brugada Brugada 5 AHA/ACC ESC I II III A B C I II IIa IIb III A B C QT long QT syndrome LQTS
抄 録 第 13 回日本小児心電学研究会 PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 25 NO. 5 ( ) VSD Brugada 1 Brugada Brugada = mm 5mm Qp/Q
抄 録 第 13 回日本小児心電学研究会 PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 25 NO. 5 (732 745) 2008 11 15 1 VSDBrugada 1 Brugada Brugada = 2 7 11 8mm 5mm Qp/Qs = 4.20 LR shunt = 80Pp/Ps = 0.93 Pp/Ps = 0.60 Rp =
untitled
RR QT V1 V2 V3 avr V4 avl V5 avf V6 V1 V2 V3 avr avl avf V4 V5 V6 Torsades de pointes () PVC ( ) late potentials T-wave alternans QT dispersion () 3 (QTDLPTWA) TWA 56 max Valt : 8.8 µv (in Z lead)
<FEFF F30D5309A30ED30AF309930E930E0005F E E C83DD004C8A C0018DF38000DD2E >
5 AFEEPVI 2010 1 2012 2 161 EEPVI ablation 5 3 mapping EnSite system St.Jude medical 5 3 ablation AF 5 3 roof line blockline AF 2 CFAE ablation EPS 237 ms 376 ms Mapping 5 activation map 3 post pacing
GL_大江班.indd
QT QT QT QT Brugada Brugada Brugada Brugada Brugada Brugada QT QTQTc Torsade de pointes T-wave alternans Notched T wave in leads Circulation Journal Vol. 71, Suppl. IV, 2007 1257 TdP QT Na + ICD QT QT
GL_小川(聡)班_D.indd
J-RHYTHM Pill-in-the-pocket Up-stream Circulation Journal Vol. 72, Suppl. IV, 2008 1639 Sicilian GambitSicilian Gambit CAST Sicilian Gambit Sicilian Gambit Sicilian Gambit Sicilian Gambit CD-ROM ACC/AHA/ESC
Symposium 46 I I II II III III 1 12 54/ narrow QRS tachycardia 139/ P V1 HIS 5 6 HIS 3 4 HIS 1 2 CS 9 10 CS 7 8 CS 5 6 CS 3 4 CS 1 2 RV 3 4 RV 1 2 100
Symposium 46 Inappropriate Sinus Tachycardia1 inappropriate sinus tachycardiaistp 100/ 1 IST 2 IST IST atrio ventricular nodal reentrant tachycardiavnrt IST 1 26 2011 24 2013 2013 7 54/ 1 narrow QRS 139/aVFP1
2004 12 16 2 1 3 2 5 2.1............... 5 2.2........... 14 2.3........................... 17 3 22 3.1.................. 22 3.2......................... 22 3.3........................ 25 3.4........................
Ventricular tachycardia recurrence as an electrical storm three years after radiofrequency ablation in a non ischemic cardiomyopathy and apical aneury
Ventricular tachycardia recurrence as an electrical storm three years after radiofrequency ablation in a non ischemic cardiomyopathy and apical aneurysm case Key words 心臓 Vol.43 SUPPL.3 2011 169 図1 初回入院時VT
CRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
”RŠœ15-3 #50 ‘¬’X 4“Z+
15 3 45 57 2000 QOL 1950 Cardiac Arrhythmia Suppression Trial 10 WPW 1 10 1990 1996 409-3898 1110 2000 5 23 2000 6 2 4 46 2 2 3 2 1 1 3 3 40 1 10 6 12 Cardiac Arrhythmia Suppression Trial CAST 4 1 3 CAST
METs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV,
2002002 Guidelines for Exercise Eligibility at Schools, Work-Sites, and Sports in Patients with Heart Diseases (JCS 2003) JR 2 3 2 3 2 2 3 2 2 3 Circulation Journal Vol. 67, Suppl. IV, 2003 309 2002002
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
九州大学学術情報リポジトリ Kyushu University Institutional Repository 高齢心疾患患者における運動機能と身体的フレイル評価の意義 内藤, 紘一九州大学大学院人間環境学府 京都橘大学健康科学部 熊谷, 秋三九州大学大学院人間環境学府 九州大学基幹教育院 九州大
九州大学学術情報リポジトリ Kyushu University Institutional Repository 高齢心疾患患者における運動機能と身体的フレイル評価の意義 内藤, 紘一九州大学大学院人間環境学府 京都橘大学健康科学部 熊谷, 秋三九州大学大学院人間環境学府 九州大学基幹教育院 九州大学キャンパスライフ 健康支援センター https://doi.org/10.15017/1800856
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
スライド 1
Wilhelm Conrad Röntgen Mr. and Mrs. Röntgen s hands (1895) X 1895 11 8 CT 0.6 500 CT NPO 0.8 /1 CT MDCT 4 1998 0.35 /1 8 16 64 2004 Takayasu CAD+PAD CT CT Angiography CTA SG Adamkiewicz PCI CABG CTA plaque
TOS7200 CD-ROM DUT PC 1.0X p.15 NEMA Vac/10 A [85-AA-0003] m : CEE7/7 : 250Vac/10 A [85-AA-0005] : GB1002 : 250Vac/10A [ ] 2016
![TOS7200 CD-ROM DUT PC 1.0X p.15 NEMA Vac/10 A [85-AA-0003] m : CEE7/7 : 250Vac/10 A [85-AA-0005] : GB1002 : 250Vac/10A [ ] 2016](/thumbs/93/112128441.jpg "TOS7200 CD-ROM DUT PC 1.0X p.15 NEMA Vac/10 A [85-AA-0003] m : CEE7/7 : 250Vac/10 A [85-AA-0005] : GB1002 : 250Vac/10A [ ] 2016")
No. IB028901 Nov. 2016 1. 11 TOS7200 2. 14 3. 19 4. 23 5. 39 6. 49 7. 51 TOS7200 CD-ROM DUT PC 1.0X p.15 NEMA5-15 125 Vac/10 A [85-AA-0003] 1 2.5 m : CEE7/7 : 250Vac/10 A [85-AA-0005] : GB1002 : 250Vac/10A
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
a 1) 2) IVUS 3)1 7 1) 2) 3) 4) a)134 )12 c)23 d)4 )1~4 c (18 p95) 8 1) 7.5MHz 2) 4 ( ) 3) 4) a)134 )12 c)23 d)4 )1~4 d 9 1) - 2) - 3) - DDR 4)
H18 http://plaza.umin.ac.jp/~wiki/cgi-in/ 1 1) 2) 3) 4) a)134 )12 c)23 d)4 )1~4 4 = = (18 p47) 3 A~D a~ 1)A- 2)B- 3)C- 4)D- a)134 )12 c)23 d)4 )1~4 18 3 4 a~ 1) - 2) - ( ) 3) - 4) - a)134 )12 c)23 d)4
35 40mmHg PaCO2 40mmHg 35mmHg CO2 PETCO2 CO2 CO2 10mmHg CPR CO2 10mmHg ROSC() CO mmHg ROSC return of spontaneous circulation ROSC 17mmHg ROSC 20
2010 ACLS Circulation Nov.2,2010 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care p640-p767 2010BLS 2010ACLS BLS Circulation, Nov2.2010 2010
老人性不整脈
資料 : QOL CHADS NOAC はじめに common disease 高齢者の不整脈の頻度, AF AVB RBBB LBBB Cardiovascular Health Study, 137 表 1 Outpatient Atarashi Cardiovascular Health Study Monolio No F M Ectopic beats Supraventricular.
24...J.e.A.u.Q _.O.t
EnSitescar breakthrough1 54 RFCA ATCARTO mapping focal AT focus CARTO mapping 2 RFCA EnSite mapping Scar2 Scar breakthrough Scar mapping Scar Exit ATPHis 1 mapping 12 His delayed potential AT ATP ATP delayed
‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01
2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation
Plastic Package (Note 12) Note 1: ( ) Top View Order Number T or TF See NS Package Number TA11B for Staggered Lead Non-Isolated Package or TF11B for S
Overture 68W ( ) 0.1 (THD N) 20Hz 20kHz 4 68W 8 38W SPiKe (Self Peak Instantaneous Temperature ( Ke)) SOA (Safe Operating Area) SPiKe 2.0 V ( ) 92dB (min) SN 0.03 THD N IMD (SMTPE) 0.004 V CC 28V 4 68W
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
NL-22／NL-32取扱説明書_操作編
MIC / Preamp ATT NL-32 A C ATT AMP 1 AMP 2 AMP 3 FLAT FLAT CAL.SIG. OVER LOAD DET. AMP 4 AMP 5 A/D D/A CONV. AMP 6 AMP 7 A/D CONV. Vref. AMP 8 AMP 10 DC OUT AMP 9 FILTER OUT AC DC OUT AC OUT KEY SW Start
ONO L 0.03mg/kg/min 1min 0.01mg/kg/min 10min M 0.03mg/kg/min 1min 0.02mg/kg/min 10min H 0.06mg/kg/min 1min 0.04mg/kg/min 10min 3 1) LSD p=0.000
ONO-1101 7 L 0.03mg/kg/min1min0.01mg/kg/min10minM 0.03mg/kg/min1min0.02mg/kg/min 10minH 0.06mg/kg/min1min0.04mg/kg/min10min 3 1) LSD p=0.0001) 30 2) FACCFSVcfc LVESWS EDA DT MH LSD p
GL_高野班_D.indd
Circulation Journal Vol. 72, Suppl. IV, 2008 1443 PCI CCU STEMI CABG ST ST1 EBM ST ST ST ST ST ST 1 EBMEvidence-Based Medicine 1444 Circulation Journal Vol. 72, Suppl. IV, 2008 ACS ST T ST CLBBB ST ACS
JPD-AMC-Catalog-Dec11.indd
GE Measurement & Control Solutions DPI620 HART - 95% 2 MPa ( 20 bar ) - 95% 10 MPa ( 100 bar ) - 0 +100 MPa ( 0 1000 bar ) 0.0025% rdg + 0.002% FS ( ma ) ( mv V ) HART PC Windows CE USB WiFi IEEE802.11
心臓 ol.42 SUPPL メインテートÑ ワソランÑ タンボコールÑ 21 メインテートÑ アーチストÑ ヘルベッサーÑ メインテートÑ ワソランÑ ベプリコールÑ サンリズムÑ シベノールÑ プロノンÑ ピメノールÑ 2001年 2009年 1st session 心房中隔起源P
case of focal atrial tachycardia arising from the posterior-inferior left atrium mimicking atrial fibrillation in the 12-lead ECG Key words 心臓 ol.42 SUPPL.4 2010 メインテートÑ ワソランÑ タンボコールÑ 21 メインテートÑ アーチストÑ
埼玉29.indb
16 Symposium 29 WPW 1 1 1 1 1 78 PSVT 4 cibenzoline 200mg, verapamil 80mg 2 OMI #7 100 X 51% HbA 1c 5.9% 12 1A 55/ V 1,2 Q 1B 116/ narrow QRS tachycardia av F V 1 P LVEDD/LVESD 55/38mm EF 58 PSVT RV His
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
R E-DO
2005 ... 6... 7... 7... 7... 8... 8... 8... 9... 9...10...10...10...10...11...11...17...19... 20...20...20...20 R E-DO...21...21...21...22...22...22...23...23... 24 2 ICU...24...24...24...24...25...26...26...26...27...27...27
<91E F193FA967B8F7A8AC28AED8A7789EF8BE38F42926E95FB89EF5F D834F F57315F E696E6464>
8:00 A A1 B B1 2F C B5 6 7 9:00 8:25~8: 8:~9: YIA 8:~9:18 1 8:~9:18 1 10:00 9:18~9:58 2 9:18~9:58 10:10~11:00 11:00 11:00~11:50 12:00 11:50~12:00 YIA 13:00 12:10~13:00 1 24 12:10~13:00 12:10~13:00 2 13:10~14:
PROGRAM【J】.fm
プログラム 1 27 1 [2F 一橋講堂 ] 9:00 9:10 9:10 10:40 1 S1-1 Ebstein Cone S1-2 S1-3 Fontan TCPC conversion S1-4 S1-5 Optimal timing of pulmonary valve replacement in repaired Tetralogy of Fallot: Review of our
( )
18 10 01 ( ) 1 2018 4 1.1 2018............................... 4 1.2 2018......................... 5 2 2017 7 2.1 2017............................... 7 2.2 2017......................... 8 3 2016 9 3.1 2016...............................
untitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
OPA134/2134/4134('98.03)
OPA OPA OPA OPA OPA OPA OPA OPA OPA TM µ Ω ± ± ± ± + OPA OPA OPA Offset Trim Offset Trim Out A V+ Out A Out D In +In V+ Output In A +In A A B Out B In B In A +In A A D In D +In D V NC V +In B V+ V +In
背景心房細動 (AF) では その持続及び病態の進行により 心房筋の電気的 構造的リモデリングと総称される心房筋の不応期の短縮 伝導時間の延長及び心房筋の脱落 線維化などの変化が生じることが知られており それを反映した電気生理学的 解剖学的諸指標によるカテーテル アブレーション後の再発予測が報告され
心臓超音波後方散乱信号 (integrated backscatter) を指標とした左心房及び左心室線維化の評価と心房細動アブレーション後再発の予知 ( 要約 ) 日本大学大学院医学研究科内科系循環器内科学専攻山口直子修了年 2016 年指導教員平山篤志 背景心房細動 (AF) では その持続及び病態の進行により 心房筋の電気的 構造的リモデリングと総称される心房筋の不応期の短縮 伝導時間の延長及び心房筋の脱落
GL改訂_野原班DST.indd
Quality of Life QOL HRQL Circulation Journal Vol. 71, Suppl. IV, 2007 1 HRQL ASO ASO ASO ASO 2 Circulation Journal Vol. 71, Suppl. IV, 2007 evidence based medicine a a b A B C,, A Quality of LifeQOL HDL
untitled
+ From Tradeoffs of Receive and Transmit Equalization Architectures, ICC006,Bryan Casper, Intel Labs Transmitter Receiver 0 magnitude (db) 0 0 30 40 50 60 0 4 frequency (GHz). Receiver Transmitter FFE
1315 (15)
(14) 1315 (15) 1316 (16) 1317 (17) 1318 (18) 1319 (19) 1320 (20) 1321 (21) 1322 quinidine, disopyramide, and procainamide in isolated atrial myocytes : Mediation by 2) Inoue H, et al: Effects of pentisomide
NL-06取扱説明書
NL-06 NL-06 NL-06 3 NL-06 NL-06 i ii -10 +50 30 90%RH 3 iii ... 1... 3... 3... 4... 5... 8... 9... 10... 11... 11... 12 WS-02... 14... 14... 15 EC-04... 16 CP-11 CP-10... 18 LR-06 LR-07 LR-04... 20...
/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
PANARAY System Digital Controller STANDBY INPUT METER TPM L -db 40 24 18 12 6 0 O R Stereo Bank 802 PRESET UTILITY LIMITER DELAY PANARAY SYSTEM DIGITAL CONTROLLER CH1/MONO INPUTS CH2 OUTPUTS CH1 CH2
JSACHD_Vol5_No2_Jul2016.book
5 2 3238 (2016) 1 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 2) 2) 1) 1) 2) 25613 19 (VF) ICD 24 (VT) (ES) (CA) VF VTICDCAgood pacemap 9VFICD VFCAES 19VFVF (Th1-4) VF (SGP) VFSGP 18ICD2 VFSGP stellate ganglion phototherapy,
2 dbx ProVocal ProVocal 3 EQ dbx / MIDI 24bit S/PDIF 44.1/48kHz Mic/Line 20dB 48V XLR XLR ProVocal 1U ProVocal Provocal 45 3 Section 1 1.1 ProVocal S/PDIF ProVocal S/PDIF RCA MIDI MIDI ProVocal XLR( )
LMC6022 Low Power CMOS Dual Operational Amplifier (jp)
Low Power CMOS Dual Operational Amplifier Literature Number: JAJS754 CMOS CMOS (100k 5k ) 0.5mW CMOS CMOS LMC6024 100k 5k 120dB 2.5 V/ 40fA Low Power CMOS Dual Operational Amplifier 19910530 33020 23900
SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO mL/kg I/E CPAP P
11 a. 2012 1 15 26 http://www1.koalanet.ne.jp/anesth_memorandum/sub19.html SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO2 20 30 8 10mL/kg I/E CPAP PEEP 27 b. CO2 ( ) SpO2 COPD PETCO2
BRC-X1000
C-455-100-02(1) BRC-X1000/H800 2016 Sony Corporation 2 3 4 5 6 4 D E 5 6 7 A B C F G 7 8 9 0 qa qs SYSTEM SELECT IN IR SELECT VISCA RS - 422 OUT OSD OFF CAMERA SETUP 1 qd 2 3 4 5 6 7 8 LAN 12V qf HDMI
JHN Journal Club 手稲渓仁会病院
JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c
高周波カテーテルアブレーションで根治した薬剤抵抗性潜在性右前中隔副伝導路の10カ月乳児例 第28巻02号0136頁
症例報告 PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 28 NO. 2 (136 142) 高周波カテーテルアブレーションで根治した薬剤抵抗性潜在性右前中隔副伝導路の 10 カ月乳児例 藤田修平 1), 中村太地 1), 臼田和生 2) 3), 渡辺一洋 市田蕗子 3) 1), 畑崎喜芳 富山県立中央病院小児科 1), 富山県立中央病院内科循環器 2),
PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 24 NO. 5 ( ) Electrophysiological Studies and Radiofrequency Catheter Ablation before Total Cavo-p
PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 24 NO. 5 (620 627) Electrophysiological Studies and Radiofrequency Catheter Ablation before Total Cavo-pulmonary Connection in Patients with Complex Congenital
STIHL Dr. Nikolas Stihl STIHL 2
EN 2017 STIHL Dr. Nikolas Stihl STIHL 2 3 STIHL STIHL 2017 STIHL MADE BY STIHL STIHL STIHL STIHL STIHL STIHLShop STIHLShop STIHL (www.stihl.co.jp/) STIHL 4 HSA 45... 12 BGA 45... 12 FSA 45... 13 MSA 120
LT 低コスト、シャットダウン機能付き デュアルおよびトリプル300MHz 電流帰還アンプ
µ µ LT1398/LT1399 V IN A R G 00Ω CHANNEL A SELECT EN A R F 3Ω B C 97.6Ω CABLE V IN B R G 00Ω EN B R F 3Ω 97.6Ω V OUT OUTPUT (00mV/DIV) EN C V IN C 97.6Ω R G 00Ω R F 3Ω 1399 TA01 R F = R G = 30Ω f = 30MHz
2
1 2 3 15 4 1 15 1 31 3 15 1 162 272 CPA 46 28 CPA 1 CPA 4 CPA 5 a. ( ) ACLS 15 5 17 b. 1 12 c. 25 29 6 7 8 CPA CPA 1 CPA Randomized Controlled Trial, RCT RCT CPA CPA 1 Dr 9 CPA CPA 15 4 1 15 1 31 CPA CPA
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( 電圧や系統安定度など ) で連系制約が発生する場合があります
熊本県数学問題正解
00 y O x Typed by L A TEX ε ( ) (00 ) 5 4 4 ( ) http://www.ocn.ne.jp/ oboetene/plan/. ( ) (009 ) ( ).. http://www.ocn.ne.jp/ oboetene/plan/eng.html 8 i i..................................... ( )0... (
LM837 Low Noise Quad Operational Amplifier (jp)
Low Noise Quad Operational Amplifier Literature Number: JAJSBB7 600 Low Noise Quad Operational Amplifier 2000 8 Converted to nat2000 DTD ds009047tl/h/9047 33020 19860602 10 V/ s ( ); 8 V/ s ( ) 25 MHz
1 2 3 P R
BL04700-101 JA DIGITAL CAMERA X-T1 Q Fn http://fujifilm.jp/personal/digitalcamera/index.html http://fujifilm-x.com/x-t1/ 1 2 3 P R y P y P y P y P Q R P V P Q Q Q Fn Fn1 Fn2 Fn3 Fn4 Fn5 Fn6 P S A M M
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
ADC121S Bit, ksps, Diff Input, Micro Pwr Sampling ADC (jp)
ADC121S625 ADC121S625 12-Bit, 50 ksps to 200 ksps, Differential Input, Micro Power Sampling A/D Converter Literature Number: JAJSAB8 ADC121S625 12 50kSPS 200kSPS A/D ADC121S625 50kSPS 200kSPS 12 A/D 500mV
LMC6082 Precision CMOS Dual Operational Amplifier (jp)
Precision CMOS Dual Operational Amplifier Literature Number: JAJS760 CMOS & CMOS LMC6062 CMOS 19911126 33020 23900 11800 ds011297 Converted to nat2000 DTD Edited for 2001 Databook SGMLFIX:PR1.doc Fixed
Digest Catalog 2017 J
2017 MULTI PROTOCOL ANALYZER LE-8200A LANIO EB SI LINEEYECO., LTD. Multi Protocol Analyzer LE-8200A MANUAL FLOW ECHO POLLING BUFFER PROGRAM Multi Protocol Analyzer LE-8200 MANUAL FLOW ECHO POLLING BUFFER
,, 2. Matlab Simulink 2018 PC Matlab Scilab 2
(2018 ) ( -1) TA Email : ohki@i.kyoto-u.ac.jp, ske.ta@bode.amp.i.kyoto-u.ac.jp : 411 : 10 308 1 1 2 2 2.1............................................ 2 2.2..................................................
MT-17J-003-a 表紙
MT-21J-003-B STP-301/451 3 -b 2002.3 Copyright 2002 Seiko Instruments Inc. All rights reserved. Printed in Japan. STP-301/451 STP STP, 1 STP-301/451 STP (MSDS Material Safety Data Sheet) ( ) MSDS STP 2
2009年133巻3号3月号.indb
Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine
i 1 40 ii Grid Dip Meter 3 10kc 1000Mc Grid Dip Meter (RF) Q Grid Dip Meter Grid Dip Meter GDM Grid Dip Meter i ii 1. Grid Dip Meter 1 1.1................... 1 1.2............... 2 1.3............... 5
<93FA97A AC C837288EA97972E786C7378>
日立ブラウン管テレビ一覧 F-500 SF-100 FMB-300 FMB-490 FMB-790 FMB-290 SMB-300 FMB-310G FMB-780 FMY-480 FMY-110 TOMY-100 FMY-520 FMY-320G SMY-110 FMY-510 SMY-490 FMY-770 FY-470 TSY-120 FY-340G FY-280 FY-450 SY-330
(1) θ a = 5(cm) θ c = 4(cm) b = 3(cm) (2) ABC A A BC AD 10cm BC B D C 99 (1) A B 10m O AOB 37 sin 37 = cos 37 = tan 37
4. 98 () θ a = 5(cm) θ c = 4(cm) b = (cm) () D 0cm 0 60 D 99 () 0m O O 7 sin 7 = 0.60 cos 7 = 0.799 tan 7 = 0.754 () xkm km R km 00 () θ cos θ = sin θ = () θ sin θ = 4 tan θ = () 0 < x < 90 tan x = 4 sin
-------------------------------------------------------------------------------------------1 ---------------------------------------------------------------------------------------------- 2 -----------------------------------------------------------------------------------------------
03J_sources.key
Radiation Detection & Measurement (1) (2) (3) (4)1 MeV ( ) 10 9 m 10 7 m 10 10 m < 10 18 m X 10 15 m 10 15 m ......... (isotope)...... (isotone)......... (isobar) 1 1 1 0 1 2 1 2 3 99.985% 0.015% ~0% E
1
1 2 3 4 5 RESISTOR TUNABLE FILTER 6 LR-SERIES 1 1 2 3 4 5 6 7.1.1 1 1 1 RF1 CF1 RF2 CF2 INPUT 14 15 16 17 18 19 2 21 22 23 24 25 26 27 28 29 3 9 8 7 6 5 4 3 2 1 84 83 82 81 8 79 78 77 R R CF CF 56k R R
DAC121S101/DAC121S101Q 12-Bit Micro Power, RRO Digital-to-Analog Converter (jp)
DAC121S101 DAC121S101/DAC121S101Q 12-Bit Micro Power, RRO Digital-to-Analog Converter Literature Number: JAJSA89 DAC121S101 12 D/A DAC121S101 12 D/A (DAC) 2.7V 5.5V 3.6V 177 A 30MHz 3 SPI TM QSPI MICROWIRE
main.dvi
A 1/4 1 1/ 1/1 1 9 6 (Vergence) (Convergence) (Divergence) ( ) ( ) 97 1) S. Fukushima, M. Takahashi, and H. Yoshikawa: A STUDY ON VR-BASED MUTUAL ADAPTIVE CAI SYSTEM FOR NUCLEAR POWER PLANT, Proc. of FIFTH
LM3886
Overture 68W ( ) 0.1 (THD N) 20Hz 20kHz 4 68W 8 38W SPiKe TM (Self Peak Instantaneous Temperature ( Ke)) SOA (Safe Operating Area) SPiKe 2.0 V ( ) 92dB (min) SN 0.03 THD N IMD (SMTPE) 0.004 V CC 28V 4
V 0 = + r pv (H) + qv (T ) = + r ps (H) + qs (T ) = S 0 X n+ (T ) = n S n+ (T ) + ( + r)(x n n S n ) = ( + r)x n + n (d r)s n = ( + r)v n + V n+(h) V
I (..2) (0 < d < + r < u) X 0, X X = 0 S + ( + r)(x 0 0 S 0 ) () X 0 = 0, P (X 0) =, P (X > 0) > 0 0 H, T () X 0 = 0, X (H) = 0 us 0 ( + r) 0 S 0 = 0 S 0 (u r) X (T ) = 0 ds 0 ( + r) 0 S 0 = 0 S 0 (d r)
NL-20取扱説明書_操作編
MIC / Preamp A C AMP 1 AMP 2 AMP 3 FLAT FLAT CAL.SIG. OVER LOAD DET. AMP 4 AMP 5 A/D D/A CONV. V ref. AMP 8 AMP 10 DC OUT AC OUT AC DC OUT DATA BUS CPU ADDRESS BUS DSP Start Pause Stop Store Mode Cont
IND EX 4 6 q 10 w B B B B2000Z B2000Z-RM 45 B2000Z-MH B B B B B1094 6
Catalog No.V3131 DIN EN ISO 9001 JIS Z 9901 Certificate:09 100 5919 TUV œœrheinland / Berlin Brandenburg Anlagentechnik GmbH ISO 14001, JIS Q 14001 Certificate-No.: 09 104 8118 IND EX 4 6 q 10 w 12 14
(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
4.4 R............................................. 13 4.5 q.............................................. 13 4.6 s....................................
2014.04.12 2014.12.12 1 3 2 4 2.1............................................ 4 2.2 Einthoven triangle........................................ 4 2.3............................................ 4 2.4.............................................
LM3876
Overture 56W ( ) 8 0.1 (THD N) 20Hz 20kHz 56W SPiKe (Self Peak Instantaneous Temperature ( Ke)) SOA(Safe Operating Area) SPiKe 2.0 V( ) 95dB(Min) SN 0.06 THD N IMD (SMTPE) 0.004 8 56W 100W SN 95dB(min)
LM2940
1A 3 1A 3 0.5V 1V 1A 3V 1A 5V 30mA (V IN V OUT 3V) 2 (60V) * C Converted to nat2000 DTD updated with tape and reel with the new package name. SN Mil-Aero: Order Info table - moved J-15 part from WG row
R1RW0408D シリーズ
お客様各位 カタログ等資料中の旧社名の扱いについて 2010 年 4 月 1 日を以って NEC エレクトロニクス株式会社及び株式会社ルネサステクノロジが合併し 両社の全ての事業が当社に承継されております 従いまして 本資料中には旧社名での表記が残っておりますが 当社の資料として有効ですので ご理解の程宜しくお願い申し上げます ルネサスエレクトロニクスホームページ (http://www.renesas.com)
PII S (96)
C C R ( 1 Rvw C d m d M.F. Pllps *, P.S. Hp I q G U W C M H P C C f R 5 J 1 6 J 1 A C d w m d u w b b m C d m d T b s b s w b d m d s b s C g u T p d l v w b s d m b b v b b d s d A f b s s s T f p s s
1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
untitled
GDS-122 User Manual... 1...1... 7... 8... 9... 10... 12...13... 14...14...15...16...17...17...18... 19...19...22...24...26...29...31...32...33... 36...36...38...39...40 TABLE OF CONTENTS... 43...43...45...46...47...48...
V(x) m e V 0 cos x π x π V(x) = x < π, x > π V 0 (i) x = 0 (V(x) V 0 (1 x 2 /2)) n n d 2 f dξ 2ξ d f 2 dξ + 2n f = 0 H n (ξ) (ii) H
199 1 1 199 1 1. Vx) m e V cos x π x π Vx) = x < π, x > π V i) x = Vx) V 1 x /)) n n d f dξ ξ d f dξ + n f = H n ξ) ii) H n ξ) = 1) n expξ ) dn dξ n exp ξ )) H n ξ)h m ξ) exp ξ )dξ = π n n!δ n,m x = Vx)
Triple 2:1 High-Speed Video Multiplexer (Rev. C
www.tij.co.jp OPA3875 µ ± +5V µ RGB Channel OPA3875 OPA3875 (Patented) RGB Out SELECT ENABLE RED OUT GREEN OUT BLUE OUT 1 R G B RGB Channel 1 R1 G1 B1 X 1 Off Off Off 5V Channel Select EN OPA875 OPA4872
http://www.ike-dyn.ritsumei.ac.jp/ hyoo/wave.html 1 1, 5 3 1.1 1..................................... 3 1.2 5.1................................... 4 1.3.......................... 5 1.4 5.2, 5.3....................
入試の軌跡
4 y O x 4 Typed by L A TEX ε ) ) ) 6 4 ) 4 75 ) http://kumamoto.s.xrea.com/plan/.. PDF) Ctrl +L) Ctrl +) Ctrl + Ctrl + ) ) Alt + ) Alt + ) ESC. http://kumamoto.s.xrea.com/nyusi/kumadai kiseki ri i.pdf
SIRIUS_CS3*.indd
SIRIUS Innovations SIRIUS SIRIUS Answers for industry. SIRIUS SIRIUS S00 S0 SIRIUS SIRIUS ZX0-ORAZ-0AB0 7.5kW 6 S00 7 8 7.5kW 9 S00 0 8.5kW S0 8.5kW S0 5 6 7 IO-Link AS-InterfaceRT 8 8US 5 6 SIRIUS SIRIUS
untitled
CoQ10 CoQ10 CoQ10 CoQ10 CoQ10 (A CoQ10 CoQ10 B CoQ10 CoQ10 C CoQ10 CoQ10 CoQ10 QOL CoQ10 QOL CoQ10 CoQ10 CoQ10 CoQ10 14 還元型 CoQ10 の摂取はインフルエンザウイルス感染に対する予防効果を示す CoQ1050CoQ10 CoQ1080CoQ10 Åberg et al., Arch
What moves your world
What moves your world 1 1.0 3 2.0 3 3.0 3 4.0 4 5.0 6 6.0 6 2 1.0 7 2.0 7 3.0 7 4.0 8 5.0 12 6.0 14 3 1.0 17 2.0 18 3.0 19 4.0 19 5.0 19 2 1 SI MPa 0.1 MPa 0.098 MPa 1 kgf cm 2 N Nm 0.007 MPa 1 psi 10
1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e
No. 1 1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e I X e Cs Ba F Ra Hf Ta W Re Os I Rf Db Sg Bh
untitled
II(c) 1 October. 21, 2009 1 CS53 yamamoto@cs.kobe-u.ac.jp 3 1 7 1.1 : : : : : : : : : : : : : : : : : : : : : : 7 1.2 : : : : : : : : : : : : : : : : 8 1.2.1 : : : : : : : : : : : : : : : : : : : 8 1.2.2